Statin therapy for coronary heart disease and its effect on stroke

Related Experiment Video

Updated: Aug 7, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Jeffrey A Switzer, David C Hess

    Current Atherosclerosis Reports
    |July 11, 2006
    PubMed

    Insights

    Statins significantly reduce stroke incidence in patients with coronary heart disease (CHD). These cholesterol-lowering drugs offer benefits beyond reducing LDL cholesterol, suggesting pleiotropic effects in stroke prevention.

    Area of Science:

    • Cardiovascular Medicine
    • Neurology
    • Pharmacology

    Background:

    • Coronary heart disease (CHD) and stroke are leading causes of death and disability.
    • Common risk factors link CHD and stroke.
    • The role of cholesterol in stroke risk is debated.

    Purpose of the Study:

    • To review the relationship between cholesterol and stroke.
    • To examine randomized trials of statins in CHD patients assessing stroke risk.
    • To explore potential mechanisms of statin-induced stroke prevention.

    Main Methods:

    • Review of existing literature on cholesterol, stroke, and statin trials.
    • Analysis of secondary endpoints from randomized controlled trials (RCTs) in CHD populations.
    • Examination of proposed pleiotropic mechanisms of statins.

    Main Results:

    • Numerous statin trials in CHD patients show reduced stroke incidence as a secondary outcome.
    • Statins appear to lower stroke risk through both cholesterol-dependent and independent pathways.
    • Evidence suggests pleiotropic effects contribute to statin's role in stroke prevention.

    Conclusions:

    • Statins offer significant stroke risk reduction in CHD patients.
    • Benefits extend beyond lipid-lowering, indicating pleiotropic mechanisms.
    • Further research into cholesterol-independent effects is warranted.

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Coronary Artery Disease IV: Preventive Measures01:26

    Coronary Artery Disease IV: Preventive Measures

    Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...